Peptide of the Week: Industry Update – Retatrutide, GLP-1s & FDA Moves Explained

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/91/07/2a/91072af7-2e2d-c0ee-15e8-84568fd9788d/mza_3183542054557180237.jpg/600x600bb.jpg

Peptide of The Week

JD Denham and Will Haas

57 episodes

4 days ago

Hosted by JD Denham and Will Haas, The Peptide of The Week Podcastis your no-BS guide to peptides, performance, and total body optimization. Whether you’re an athlete, a high performer, or just hungry to feel better, move better, and live stronger this show’s for you. JD and Will dive deep into real-world protocols, hard-earned lessons, and the science behind what actually works. With expert guests and raw conversations, you’ll get everything from cutting-edge peptide talk to diet, training, recovery, and mindset. No fluff. No filters. Just the tools to rebuild your body and upgrade your life.

Health & Fitness

RSS

All content for Peptide of The Week is the property of JD Denham and Will Haas and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/43782689/43782689-1762742774377-6e24647f57c97.jpg

Peptide of the Week: Industry Update – Retatrutide, GLP-1s & FDA Moves Explained

Peptide of The Week

23 minutes 27 seconds

2 weeks ago

Peptide of the Week: Industry Update – Retatrutide, GLP-1s & FDA Moves Explained

Welcome back, warriors! In this week’s special episode of Peptide of the Week, JD Denham and William T. Haas are joined by peptide researcher and clinical expert Paul Bakhtiar to break down the biggest developments shaking up the entire peptide industry.

From FDA crackdowns to the future of GLP-1s like Retatrutide, this episode gives you the real insider breakdown of what’s happening, why it matters, and what you should do right now if you’re using or selling peptides.

We cover:

⚠️ Retatrutide: What’s changing & when

– Big Pharma is moving fast to monopolize Retatrutide via FDA approval

– Once approved, it will no longer be available through research-use sites

– Access will be limited to prescription only via 503A/503B pharmacies & telehealth

– Expect price increases of 50–100% compared to current availability

💉 What does this mean for GLP-1 users?

– Stock up NOW if you’re using Retatrutide (powder can last 2+ years unreconstituted)

– Semaglutide & Tirzepatide may still be available for a time, but not forever

– New rules are expected by Q1 2026, if not sooner

– Telehealth will become the main legal route for GLP-1s and other “controlled” peptides

📉 What about other peptides (BPC-157, TB-500, MOTC, etc.)?

– The FDA is quietly reclassifying peptides as “biologics” to open them up for patents

– 25–40 peptides are expected to become FDA approved in the next 12–18 months

– Research-use availability will continue for now, but eventually move to doctor-prescribed only

💣 Why this proves peptides are the real deal

– Peptides work that’s why Big Pharma is jumping in

– The move to medicalize & retailize peptides is proof they’re not fringe they’re the future

– Good news: this also removes bad actors & fake COAs from the market

📌 Whether you’re a casual user or deep in the industry this episode is a must-listen for truth over headlines and clarity over fear.

💬 Got questions? Drop them in the comments and we’ll keep unpacking this in future episodes.

📺 Subscribe for weekly deep dives into the truth about performance, healing, and longevity. No fluff. No fear. Just facts.

Stay Connected & Follow Us!

JD's Instagram: https://www.instagram.com/jd_denham_fit

JD's Facebook: https://www.facebook.com/people/JD-Denham/61563578940850/

Wills Instagram: https://www.instagram.com/williamthaas/

Paul Bakhtiar's Instagram: https://www.instagram.com/paulbakhtiar/